MultiCell Technologies Delivered Presentation at 2012 ASCB Meeting
WOONSOCKET, R.I., Dec. 26, 2012 /PRNewswire/ — MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) presented at the 2012 American Society for Cell Biology® (ASCB®) Annual Meeting in San Francisco, CA, on Tuesday, December 18. Simona Bot, M.D. presented preclinical research results in an abstract titled “Short Synthetic Double Stranded RNA with Dual Activity – Oncolytic and Immune Modulatory – for Hepatocellular Carcinoma.”
This research was supported by MultiCell via a sponsored research grant with the laboratory of Anand Ghanekar, M.D., Ph.D. at University Health Network, Toronto General Hospital Research Institute, Ontario, Canada. The scientific results presented by Dr. Bot added key information regarding the capability of MCT-485 to elicit highly pro-inflammatory cytokine by human monocytes, and death of human liver cancer cells, mostly through a mechanism distinct from apoptosis. Together with the data previously presented at the Association of Cancer Immunotherapy (CIMT annual meeting, May 2012, Mainz, Germany) describing the direct anti-tumor cell effect of MCT-485 on multiple human liver cancer cell lines in vitro, the novel scientific evidence supports the model that this synthetic dsRNA molecule could mediate a two-pronged effect within the tumor environment: destruction of the tumor cells and activation of the stromal monocytes. The latter could amplify the immune system’s capability to fight off tumor over a longer timeframe.
Altogether, these data sets, generated for the first time with MCT-485 manufactured using a state of the art process, as presented at CIMT and ASCB® 2012, support further studies exploring the preclinical safety, effectiveness and clinical utility of this candidate as a novel therapeutic agent for hepatocellular carcinoma.
About MultiCell Technologies, Inc.
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.
For more information about MultiCell Technologies, please visit http://www.multicelltech.com. For more detailed background on the presentation refer to the September 27 news release, and the poster archived on the site.
Caution Regarding Forward-Looking Statements
Any statements in this press release about MultiCell’s expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). These statements are often, but not always, made through the use of words or phrases such as “believe”, “will”, “expect”, “anticipate”, “estimate”, “intend”, “plan”, “forecast”, “could”, and “would”. MultiCell bases these forward- looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our products as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties MultiCell faces, see documents that MultiCell files with the Securities and Exchange Commission, including MultiCell’s report on Form 10-K for the fiscal year ended November 30, 2011, and all of MultiCell’s quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.
SOURCE MultiCell Technologies, Inc.